



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/446,543	12/20/1999	SHUJI HINUMA	2472US0P	2478

23115 7590 05/07/2003

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC
INTELLECTUAL PROPERTY DEPARTMENT
475 HALF DAY ROAD
SUITE 500
LINCOLNSHIRE, IL 60069

EXAMINER

MITRA, RITA

ART UNIT	PAPER NUMBER
1653	18

DATE MAILED: 05/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

File Copy

Office Action Summary	Application N .	Applicant(s)
	09/446,543	HINUMA ET AL.
	Examiner Rita Mitra	Art Unit 1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 22 January 2003.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 20-35 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 20-35 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). 18 .

2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . 6) Other:

File Copy

DETAILED ACTION

Status of the Claims

Applicants' amendment and response to office action dated October 22, 2002, filed on January 22, 2003 (paper #17) is acknowledged. Claims 1-4, 6, 10, 11, 13, 14 and 17-19 have been cancelled. New claims 20-35 have been added. Therefore, claims 20-35 are currently pending and are under examination.

Response to Remarks and Arguments

Withdrawal of Rejections

The rejection of claims 1-4, 6, 10, 11, 13, 14 and 17-19 under **35 U.S.C. § 112, first paragraph** is moot in view of Applicants' cancellation of the claims.

The rejection of claims 1-3 under **35 U.S.C. § 102(a) and 102(e)** as being unpatentable over Hinuma et al. is moot in view of Applicants' cancellation of claims.

New ground of rejection

Objection to Specification

Applicants have not identified by assigning a SEQ ID NO to the sequence provided for 19P2-L31 (see page Example 21, page 93-95). Attorney Mark Chao in a telephonic interview on April 30, 2003 (see attachment) has assigned SEQ ID NO: 5 to the sequence of 19P2-L31, however, specification fails to give this information. An appropriate correction would overcome this objection. To move the prosecution from its present status the sequence given in 19P2-L31 is interpreted as the sequence given in SEQ ID NO: 5 and the claims are examined accordingly.

Rejections under 35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 20-35 are rejected under **35 U.S.C. 112, first paragraph**, because the specification, while being enabling for a method for promoting prolactin secretion comprising administration a ligand polypeptide of full length sequence set forth in SEQ ID NO: 5; does not reasonably provide enablement for a variable of that sequence or fragments generated from any position located on the sequence of SEQ ID NO: 5. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Applicants' reasons and arguments in response to the rejection are fully considered, however not found persuasive. The traversal is addressed along with the rejection as set forth below:

Claims 20-35 encompass a method for promoting prolactin secretion in a mammal that comprises a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claim 20 (i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74 fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claim 20 (ii)); an amino acid sequence of SEQ ID NO: 5 and 61 (claims 21, 22, 23); a method for promoting lactation in a mammal that comprises a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claim 24 (i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74 fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claim 24 (ii)); an amino acid sequence of SEQ ID NO: 5 and 61 (claims 25, 26, 27); a method for treating hypoovarianism in a mammal that comprises a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claim 28 (i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74 fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claim 28 (ii)); an amino acid sequence of SEQ ID NO: 5 and 61 (claims 29, 30, 31); a method for eliciting an aphrodisiac effect in a mammal that comprises a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claim 32 (i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74

fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claim 32 (ii)); an amino acid sequence of SEQ ID NO: 5 and 61 (claims 33, 34, 35).

The specification, however, only discloses (see page 4-5) without data to support the findings, which state that the ligand polypeptide of the agent is a polypeptide comprising an amino acid sequence represented by SEQ ID NO: 73 or a substantial equivalent thereto (page 4, lines 11-15). While defining “substantial equivalent” at page 19 specification indicates that it means the binding activity of the ligand and the receptor and physical characteristics are substantially same, and polypeptides containing the substitution, deletion or insertion would be considered to be substantially equivalent to polypeptides lacking the substitution deletion or insertion.

There are no indicia that the present application enables the full scope in view of the amino acid sequences corresponding to a variable or fragment of the sequence as set forth in SEQ ID NO: 5 as discussed in the following stated rejection. The specification further indicates (see page 22) that the ligand polypeptide of the present invention can be changed or mutated by substitution, deletion, addition or modification to a polypeptide, which is stable against heat or proteases, or a polypeptide whose physiological function is activated. The present application provides no indicia and no teaching/guidance as to how the full scope of the claims is encompassed. The description given at pages 20-22 or 29-30 are not specific, also no biological activities are described for the variants and fragments that would be generated from SEQ ID NO: 5.

The breadth of the claims is broad and encompasses an unspecified amount of variants regarding the ligand polypeptide of SEQ ID NO: 73, SEQ ID NO: 5 as biological active variants, which are not specifically described or demonstrated in the specification. Moreover, amended claims do not remove the deficiency to overcome the scope rejection as discussed below:

Claims 20-23 are directed to a method for promoting prolactin secretion in a mammal that comprises administering a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claim 20 (i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74 fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claim 20 (ii)); an amino acid sequence of SEQ ID NO: 5 and 61 (claims 21, 22, 23). The specification describes a ligand

polypeptide for G protein-coupled receptor protein and shows the influence of this polypeptide on prolactin secretion (see Examples 46, 47, 49). None of the examples provide any indication that the ligand polypeptide fragments or variants would influence the promotion of prolactin secretion thus part of claim 20 and 21-23 (variables and fragments) is not enabled by the description. Specification at pages 67-69 provides a general description of the application of the ligand polypeptide and also describes an administration of the polypeptide (Example 49) to rats that increases prolactin secretion. However specification fails to provide description for the use of the variants of ligand polypeptides in the claimed method. For the reasons set forth above, undue experimentation is necessary to make and use the claimed fragments that retain the property of promoting prolactin secretion.

Furthermore no biological activities were attributed to the recited variants and the structural information was limited (see specification page 21, lines 22-36, page 22, lines1-6). There is no disclosure about the biological activities of the claimed variants. Identification of the ligand polypeptide19P2L31 (SEQ ID NO: 5) is described in Example 21 of the specification and its function for promoting prolactin secretion were described in *in vivo* assay of Examples 46, 47, however specification fails to provide any description or demonstration of a variant of ligand polypeptide of SEQ ID NO: 73 or SEQ ID NO: 74 fused to SEQ ID NO: 73 or SEQ ID NO: 61 sequence promoting prolactin secretion. For these reasons, it requires undue experimentation to make the claimed invention, especially where in claims 20-23, variants would have been included by the claims and for which the specification does not describe with particularity as to retention of function. Without any guidance or suggestions a skilled artisan would not be able to predict the structure of a variant that would demonstrate the same activity as the activity of the ligand polypeptide sequence of SEQ ID NO: 5 and SEQ ID NO: 73 and SEQ ID NO: 61. Thus, for the reasons set forth above, undue experimentation is required to make and use the claimed variants.

Claims 24-35 are directed to the method of use of the ligand polypeptide for promoting lactation in a mammal that comprises a ligand polypeptide, or a salt thereof, wherein the ligand polypeptide comprising an amino acid sequence of SEQ ID NO: 73 (claims 24 (i), 28(i) and 32(i)), wherein said ligand polypeptide sequence comprises an amino acid sequence of SEQ ID NO: 74 fused to the N-terminal of the amino acid sequence of SEQ ID NO: 73 (claims 24 (ii),

28(ii) and 32(ii) for promoting lactation of a mammal (claims 24-27), for treating hypoovarianism (claims 28-31), and for eliciting an aphrodisiac effect (claims 32-35). However, there is no disclosure of the use of any variant for any treatment or for any induction/influence as claimed for the ligand polypeptide. For these reasons, it requires undue experimentation to make the claimed invention.

As discussed above, the specification provides only a generic description of how a variety of variants of ligand polypeptide can be generated (page 19-21), no specific guidance is provided on the generation of the fragments that demonstrate the biological activity of the ligand sequences of SEQ ID NO: 73 or SEQ ID NO: 74. There are no working examples of these variants in the specification. While the specification in Example 46 and 47 describes and demonstrates that the ligand polypeptide set forth in SEQ ID NO: 73 having prolactin secretion function, there is no disclosure about the biological activities of the claimed variants of ligand polypeptide. Since the specification fails to provide sufficient guidance on the structure and function of the various variants, it is necessary to have additional guidance on the identities of fragments to carry out further experimentation to assess their property of having prolactin secretion function.

The prior art has shown an agent as well as a ligand polypeptide for a G protein-coupled receptor protein for modulating prolactin secretion (see section below of 102 rejection), however, the general knowledge and level of the skill in the art do not supplement the omitted description, the specification needs to provide specific guidance on the structure and function for various amino acid sequences to be considered enabling for variants/fragments for ligand polypeptide. Furthermore, prior art demonstrates the enablement of a specific ligand polypeptide that couples with a specific G protein-coupled receptor to modulate pituitary function, prior art doesn't describe the enablement of any agent comprising any ligand polypeptide that binds with any G protein-coupled receptor protein to modulate the prolactin secretion as claimed in the instant application. Moreover, the prior art does not demonstrate enablement of any variants or fragments of such a ligand polypeptide.

Applicants have submitted two references in support of their assertion. Hinuma et al. (Nature, 393, 272-276, 1998) and Kawamata et al. (Endocrine, 12, 215-221, 2000) references have been reviewed. However none of the articles describe any mutants/fragments that promote the prolactin secretion as claimed in the instant invention. Therefore, these references do not overcome the scope rejection.

In consideration of each of factors 1-8, it is apparent that there is undue experimentation because in summary, the scope of the claim is broad, the working example does not demonstrate the claimed variants, the guidance/the teaching in the specification is limited, and the outcome is unpredictable for the various modified forms, it is necessary to have additional guidance and to carry out further experimentation to assess the property of the variants. Therefore, due to large quantity of experimentation necessary to determine an activity or property of the disclosed ligand polypeptide and the fragments thereof, such that it can be determined how to use the claimed ligand polypeptide, the lack of direction/guidance presented in the specification regarding same, the absence of working examples directed to same, the complex nature of the invention, the specification fails to teach the skilled artisan how to make and use the claimed invention.

Rejections under 35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 20-35 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 20-35 are indefinite because of the use of the term “represented.” The term “represented” renders the claims indefinite because it is not clear what are those amino acids of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, and SEQ ID NO: 64 respectively that are represented in these claims.

Claims 20-35 are indefinite because they lack essential steps as claimed in the methods. The omitted steps are: the site and method of administration, the therapeutically effective amount of the agent and a step whereby the desired outcome using the claimed polypeptide can be determined.

Rejections under 35 U.S.C. § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 20-23 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by Hinuma et al. (US Patent 6, 228,984, Issued May 8, 2001; 102(e) date: February 6, 1997). Hinuma et al. teach a novel ligand polypeptide for the G protein-coupled receptor protein, having an amino acid sequence set forth in SEQ ID NO: 73 or its substantial equivalent thereto, or its amide or ester or salt thereof (US '984 technical field col. 1; col. 2 lines 36-39 and claim 1), wherein the pharmaceutical composition containing the said polypeptide is a pituitary function modulator ('984, col. 3, lines 15-17). Hinuma's polypeptide has 96.3% sequence identity to SEQ ID NO: 73 (see alignment result, Database: A_Geneseq_032802, AC NO: AAW31394) (claim 20 (i)). Hinuma et al. also teach a polypeptide which comprises an amino acid sequence wherein the peptide of SEQ ID NO: 74 is added to the N-terminus of the polypeptide comprising the

amino acid sequence of SEQ ID NO: 73 ('984 col. 4, lines 12-16), wherein the fused polypeptide has 94.2% sequence identity to SEQ ID NO: 74 fused to SEQ ID NO: 73 (see alignment result, Database: A_Geneseq_032802, AC NO: AAW31391) (claim 20 (ii)). Further, Hinuma et al. teach a polypeptide variable/fragment (see '984, col. 2, lines 40-47 and claim 2) that comprises an amino acid sequence having 100% sequence identity to SEQ ID NO: 61 (see alignment result, Database: A_Geneseq_032802, AC NO: AAW31391) (claim 21). Hinuma's polypeptide having SEQ ID NO: 73, SEQ ID NO: 74 and the fused products and variables/fragments thereof; a variable having SEQ ID NO: 61 are considered for the agent for promoting prolactin secretion which comprises an isolated ligand polypeptide having amino acid sequence of SEQ ID NO: 73, SEQ ID NO: 74 and the fused products and variables thereof, a variable having SEQ ID NO: 61 (claims 21-23). Therefore, claims 21-23 of the instant application are anticipated by Hinuma et al. because items (i) through (xii) of claim 21 are fragments and variables as to the exact sequence.

In response Applicants urge at page 11 that new claims are directed to a method neither taught nor suggested by the '984 reference of Hinuma. Applicants' argument is not persuasive because '984 indicates that the pharmaceutical composition containing the polypeptide and the partial peptide is a pituitary function modulator (see '984 col 3, lines 7-12), thus anticipating claims 20-23. Furthermore, Applicants indicate at page 10 that the activity of prolactin secretion of the peptides claimed is proved in (i) Examples 46, 47 and 49 of the specification, (ii) the submitted Nature article, and in (iii) the submitted Endocrine article. Applicants' statement is noted, however as to address (i), only peptide 19P2-L31 (SEQ ID NO: 5) is proved in Examples 46, 47, 49. Not all the peptides and also not SEQ ID NO: 61 as indicated at page 11, lines 17-19 of response. As to address (ii) Nature article anticipates claims 20-23 in following rejection:

Claims 20-23 are rejected under 35 U.S.C. 102(a) as being anticipated by Hinuma et al. (Nature, vol 393, No.6682, pp272-276, 21 May, 1998). Hinuma et al. teach a prolactin-releasing peptide in the brain (PrRP31), having 100% sequence identity to SEQ ID NO: 61 (see alignment result, Database: SwissProt_40, AC NO: P81277, 30 May 2000) (claims 21-23), wherein addition of PrRP31 to the culture increased the secretion of PRL prolactin from RC-4B/C cells within 30 min, also PrRP31 promoted the secretion of PRL from rat anterior pituitary cells in a perfusion assay (see page 273, col 2, paragraph 2, and Fig. 4a and 4c) Hinuma's polypeptide

has 96.3% sequence identity to SEQ ID NO: 73 (see alignment result, Database: SwissProt_40, AC NO: P81277) (claim 20 (i)) and has 94.2% sequence identity to SEQ ID NO: 74 fused to SEQ ID NO: 73 (see alignment result, Database: SwissProt_40, AC NO: P81278) (claim 20 (ii)). Thus method of use of Hinuma's peptide is considered for the method of claims 20-23 of the instant application.

Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Inquiries

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rita Mitra whose telephone number is (703) 605-1211. The Examiner can normally be reached from 9:30 a.m. to 6:30 p.m. on weekdays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Christopher Low, can be reached at (703) 308-2923. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology

Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Fax Center number is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



Rita Mitra, Ph.D.
April 30, 2003



CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600